Crosslinked, porous polymers for controlled drug delivery
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C08L-075/00
C08G-073/12
A61K-009/22
출원번호
US-0523236
(1983-08-15)
발명자
/ 주소
Mueller, Karl F.
Heiber, Sonia J.
출원인 / 주소
Ciba-Geigy Corporation
대리인 / 주소
Hall, Luther A. R.
인용정보
피인용 횟수 :
148인용 특허 :
6
초록▼
A controlled-release, drug-delivery composition which comprises (A) a crosslinked copolymer, capable of swelling in ethanol to give a swollen copolymer containing at least 40% by weight of ethanol, and capable of swelling in water to give a swollen copolymer containing no more than 20% by weight of
A controlled-release, drug-delivery composition which comprises (A) a crosslinked copolymer, capable of swelling in ethanol to give a swollen copolymer containing at least 40% by weight of ethanol, and capable of swelling in water to give a swollen copolymer containing no more than 20% by weight of water, where the swelling ratio (% ethanol: % water) is 2:1 to 22:1, which comprises the copolymerization product of (a) 50 to 99% by weight of said copolymer of a water-insoluble monoolefinic monomer or (a) with 0 to 45% by weight of total monomers of a water-soluble monoolefinic monomer, with (b) 50 to 1% by weight, but not more than 20 mol % of a divinyl or polyvinyl crosslinking agent; and (B) an effective amount of a pharmaceutical medicament is useful for the controlled and prolonged release of drugs when taken orally.
대표청구항▼
1. A controlled-release, drug-delivery carrier composition which comprises a crosslinked copolymer, capable of swelling in ethanol to give a swollen copolymer containing at least 40% by weight of ethanol, and capable of swelling in water to give a swollen copolymer containing no more than 20% by
1. A controlled-release, drug-delivery carrier composition which comprises a crosslinked copolymer, capable of swelling in ethanol to give a swollen copolymer containing at least 40% by weight of ethanol, and capable of swelling in water to give a swollen copolymer containing no more than 20% by weight of water, where the % ethanol: % water is 2:1 to 22:1 respectively, which copolymer is the copolymerization product of (a) 50 to 99% by weight of said copolymer of (aa) a water-insoluble monoolefinic monomer, or mixture of said monomers, or mixture of said monomers with 0 to 45% by weight of total monomers of (bb) a water-soluble monolefinic monomer, or mixture of said water-soluble monomers, with (b) 50 to 1% by weight of said copolymer of a divinyl or polyvinyl crosslinking agent having a molecular weight of 100 to 10,000, but where (b) is not more than 20 mol% of component (a). 2. A composition according to claim 1 wherein the swollen copolymer the % ethanol: % water is 3:1 to 15:1 respectively. 3. A composition according to claim 2 wherein the swollen copolymer the % ethanol: % water is 4:1 to 8:1 respectively. 4. A composition according to claim 1 where in the copolymer at least a third by weight of the water-insoluble monomer of component (a) is a monomer with an alkyl group of 4 to 21 carbon atoms. 5. A composition according to claim 1 wherein the copolymer is the copolymerization product of 75-98% by weight of component (a) and 25-2% by weight of component (b). 6. A composition according to claim 1 wherein component (a) comprises 70-95% by weight of water-insoluble monomer (aa) and 30-5% by weight of water-soluble monomer (bb). 7. A composition according to claim 1 wherein component (a) is 75-0% by weight of methyl acrylate, methyl methacrylate or mixture thereof, and 25-100% by weight of a C 4 -C 10 alkyl acrylate or methacrylate or mixture thereof. 8. A composition according to claim 1 wherein the water-insoluble monomer of component (a) is methyl methacrylate, n-butyl acrylate, n-butyl methacrylate, 2-ethylhexyl acrylate, n-octyl acrylate, n-octyl methacrylate, glycidyl methacrylate, vinyl acetate or mixtures thereof. 9. A composition according to claim 1 wherein 10-60% by weight of component (a) is n-butyl acrylate or 2-ethylhexyl acrylate. 10. A composition according to claim 1 wherein the water-soluble monomer of component (a) is N-vinyl-2-pyrrolidone, 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, acrylic acid, methacrylic acid, N,N-dimethylacrylamide, 2-dimethylaminoethyl methacrylate or mixtures thereof. 11. A composition according to claim 1 where the crosslinking agent of component (b) is a terminal diolefinic hydrophobic macromer having a molecular weight from about 400 to about 8000, said macromer having the formula ##STR## wherein R 1 is a chain having a molecular weight from about 200 to about 8000, which is the residue of a poly(propylene oxide) or poly(tetramethylene oxide) glycol having ether linkages; R 2 is hydrogen, methyl or --CH 2 COOR 4, wherein R 4 is hydrogen or an alkyl group with up to 10 carbon atoms; R 3 is hydrogen or COOR 4, with the proviso that at least one of R 2 and R 3 is hydrogen; X is oxa, --COO--, or --CONR 5 -- is hydrogen or alkyl with up to 5 carbon atoms and Y is a direct bond or the radical --R 6 --Z 1 --CO--NH--R 7 --NH--CO--Z 2 --, wherein R 6 is linked to X and represents branched or linear alkylene with up to 7 carbon atoms; Z 1 and Z 2 is oxa or NR 5 and R 7 is the diradical of an aliphatic or aromatic diisocyanate, with the proviso that in case X is oxa, Y is different from a direct bond, and R 2 and R 3 are hydrogen. 12. A composition according to claim 11 wherein R 1 is polypropylene oxide or polytetramethyleneoxide chain with a molecular weight of about 600 to about 4000. 13. A composition according to claim 11 wherein said macromer is a polytetramethyleneoxide glycol with a molecular weight of about 600 to about 4000, endcapped with toluene or isophorone diisocyanate and reacted with 2 moles of a hydroxyalkyl acrylate or methacrylate, wherein alkyl has 2 to 4 carbon atoms. 14. A composition according to claim 1 wherein the crosslinking agent (b) is a C 2 -C 6 alkylene diacrylate, a C 2 -C 6 alkylene dimethacrylate, 3-oxapentamethylene diacrylate, 3-oxapentamethylene dimethacrylate, trimethylolpropane triacrylate or mixtures thereof. 15. A composition according to claim 1 where the copolymer is the copolymerization product of 85-99% of component (a) and 15-1% of component (b), where (a) is 15-50% by weight of methyl methacrylate, 15-70% by weight of 2-ethylhexyl acrylate, n-butyl acrylate or n-octyl acrylate, 5-15% by weight of N-vinyl-2-pyrrolidone and 0-25% by weight of 2-hydroxyethyl methacrylate.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (6)
Dobo Janos (Budapest HUX) Takacs Erzsebet (Budapest HUX) Hortobagyi Gyozo (Budapest HUX) Skvorecz nee Hajnoczy Marianne (Budapest HUX) Kolbe Ilona (Budapest HUX) Hoffmann nee Vas Katalin (Budapest HU, Coating ensuring a controlled release of active ingredients of biologically active compositions, particularly pharmaceut.
Mueller Karl F. (New York NY) Heiber Sonia J. (Bedford Hills NY) Plankl Walter L. (Yorktown Heights NY), Process for preparing hydrogels as spherical beads of large size.
Gotsche, Michael; Kolter, Karl; Sanner, Axel; Angel, Maximilian; Leinenbach, Alfred, APPLICATION OF WATER-SOLUBLE OR WATER-DISPERSIBLE POLYMERIZATES WHICH CONTAIN POLY-ETHER AND WHICH ARE USED AS A COATING AGENT, A BINDING AGENT AND/OR AS A FILM-FORMING AUXILIARY AGENT IN PHARMACEUTI.
Dempski Robert E. (Dresher PA) Scholtz Edward C. (King of Prussia PA) Nibbelink Donald W. (Lansdale PA) Reines Scott A. (New Hope PA), Controlled release combination of carbidopa/levodopa.
Oshlack Benjamin (New York NY) Chasin Mark (Manalapan NJ) Pedi ; Jr. Frank (Yorktown Heights NY), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Rodgers, James D.; Shepard, Stacey; Zhu, Wenyu; Shao, Lixin; Glenn, Joseph, Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors.
Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase.
Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors.
Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors.
Rodgers, James D.; Shepard, Stacey; Fridman, Jordan S.; Vaddi, Krishna, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors.
Good William R. (Suffern NY) Mikes John (Madison NJ) Sikora Joseph (Wanaque NJ), Hydrogels with increased organic solvent soluble active agent loading capacity, their preparation and the use thereof.
Polansky Jon R. (Mill Valley CA) Bloom Ernest (Alamo CA) Fauss Donald J. (San Francisco CA), Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division.
Polansky Jon R. (Mill Valley CA) Bloom Ernest (Alamo CA) Fauss Donald J. (San Francisco CA), Methods for the cyto-protection of the trabecular meshwork.
Rodgers, James D.; Shepard, Stacey; Zhu, Wenyu; Shao, Lixin; Glenn, Joseph, Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors.
Rodgers, James D.; Li, Hui-Yin, Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
Rodgers, James D.; Li, Hui-Yin, Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
Rodgers, James D.; Li, Hui-Yin, Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
Rodgers, James D.; Li, Hui-Yin, Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
Rodgers, James D.; Li, Hui-Yin, Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
Goldberg, David A.; Howson, David C.; Metzger, Steven W.; Buttry, Daniel A.; Saavedra, Steven Scott, Sensitive and rapid determination of antimicrobial susceptibility.
Oshlack Benjamin ; Chasin Mark ; Pedi ; Jr. Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack, Benjamin; Chasin, Mark; Pedi, Jr., Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Oshlack,Benjamin; Chasin,Mark; Pedi, Jr.,Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Heafield Joanne,GBX ; Knott Trevor John,GBX ; Leslie Stewart Thomas,GBX ; Malkowska Sandra Therese Antoinette,GBX ; Miller Ronald Brown,CHX ; Prater Derek Allan,GBX ; Smith Kevin John,GBX, Sustained release compositions and a method of preparing pharmaceutical compositions.
Heafield Joanne,GB2 ; Knott Trevor John,GB2 ; Leslie Stewart Thomas,GB2 ; Malkowska Sandra Therese Antoinette,GB2 ; Miller Ronald Brown,CHX ; Prater Derek Allan,GB2 ; Smith Kevin John,GB2, Sustained release compositions of morphine and a method of preparing pharmaceutical compositions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.